fear of hypoglycaemia and gain in body weight are barriers for initiation of insulin therapy . modern insulin analogues are a convenient new approach or tool to glycaemic control , associated with low number of hypoglycaemia and favourable weight change . a1chieve , a multinational , 24-week , non - interventional study , assessed the safety and effectiveness of insulin analogues in people with t2 dm ( n = 66,726 ) in routine clinical care . this short communication presents the results for patients enrolled from rabat - sale - zemmour - zaer region , morocco . please refer to editorial titled : the a1chieve study : mapping the ibn battuta trail .. the patient characteristics for the entire cohort , divided as insulin - nave and insulin users are shown in the table 1 . the majority of patients ( 41.7% ) started on or were switched to biphasic insulin aspart . other groups were insulin detemir ( n = 150 ) , insulin aspart ( n = 11 ) , basal insulin plus insulin aspart ( n = 45 ) and other insulin combinations ( n = 41 ) . overall demographic data after 24 weeks of treatment , overall hypoglycaemia reduced from 13.4 events / patient - year to 2.7 events / patient - year in insulin user group while hypoglycaemic events increased from 0.7 events / patient - year to 0.9 events / patient - year in the insulin nave group . however , this hypoglycaemia incidence in insulin naive group at 24 weeks was still lower than that observed in insulin users at baseline . sadrs were reported in 0.5% of insulin users . blood pressure and quality of life improved after 24 weeks . although lipid profile improved in the total cohort , but the finding was limited by number of observations [ tables 2 and 3 ] . all parameters of glycaemic control improved from baseline to study end in the total cohort [ table 4 ] . overall efficacy data of the total cohort , 177 patients started on biphasic insulin aspart  ogld , of which 79 ( 44.6% ) were insulin nave and 98 ( 55.4% ) were insulin users . after 24 weeks of treatment , hypoglycaemic events reduced from 8.8 events / patient - year to 3.6 events / patient - year in insulin user group whereas hypoglycaemia increased from 1.3 events / patient - year to 2.2 events / patient - year in insulin nave group . quality of life improved at the end of the study [ tables 5 and 6 ] . biphasic insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin nave and insulin user groups [ table 7 ] . biphasic insulin aspartoral glucose - lowering drug efficacy data of the total cohort , 45 patients started on basal + insulin aspart  ogld , of which 4 ( 8.9% ) were insulin nave and 41 ( 91.1% ) were insulin users . after 24 weeks , hypoglycaemic events reduced from 36.5 events / patient - year to 3.1 events / patient - year in insulin user group . basal+insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were basal + insulin aspart  oglds [ table 10 ] . basal+insulin aspartoral glucose - lowering drug efficacy data of the total cohort , 150 patients started on insulin detemir  ogld , of which 116 ( 77.3% ) were insulin nave and 34 ( 22.7% ) were insulin users . after 24 weeks of starting or switching to insulin detemir , hypoglycaemia reduced from 13.0 events / patient - year to 0.5 events / patient - year in insulin users and from 0.1 events / patient - year to 0.0 events / patient - year in insulin nave group . an improvement in quality of life was also observed at the end of the study [ tables 11 and 12 ] . insulin detemiroral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir  oglds for insulin - nave group while mean hba1c and fpg values improved for insulin users [ table 13 ] . insulin detemiroral glucose - lowering drug efficacy data of the total cohort , 11 patients started on insulin aspart  ogld of which 2 ( 18.2% ) were insulin nave and 9 ( 81.8% ) were insulin users [ table 14 ] . insulin aspartoral glucose - lowering drug safety data mean hba1c and mean pppg improved from baseline to study end in those who started on or were switched insulin aspart  oglds [ table 16 ] . of the total cohort , 177 patients started on biphasic insulin aspart  ogld , of which 79 ( 44.6% ) were insulin nave and 98 ( 55.4% ) were insulin users . after 24 weeks of treatment , hypoglycaemic events reduced from 8.8 events / patient - year to 3.6 events / patient - year in insulin user group whereas hypoglycaemia increased from 1.3 events / patient - year to 2.2 events / patient - year in insulin nave group . quality of life improved at the end of the study [ tables 5 and 6 ] . biphasic insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin nave and insulin user groups [ table 7 ] . of the total cohort , 45 patients started on basal + insulin aspart  ogld , of which 4 ( 8.9% ) were insulin nave and 41 ( 91.1% ) were insulin users . after 24 weeks , hypoglycaemic events reduced from 36.5 events / patient - year to 3.1 events / patient - year in insulin user group . basal+insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were basal + insulin aspart  oglds [ table 10 ] . of the total cohort , 150 patients started on insulin detemir  ogld , of which 116 ( 77.3% ) were insulin nave and 34 ( 22.7% ) were insulin users . after 24 weeks of starting or switching to insulin detemir , hypoglycaemia reduced from 13.0 events / patient - year to 0.5 events / patient - year in insulin users and from 0.1 events / patient - year to 0.0 events / patient - year in insulin nave group . an improvement in quality of life was also observed at the end of the study [ tables 11 and 12 ] . insulin detemiroral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir  oglds for insulin - nave group while mean hba1c and fpg values improved for insulin users [ table 13 ] of the total cohort , 11 patients started on insulin aspart  ogld of which 2 ( 18.2% ) were insulin nave and 9 ( 81.8% ) were insulin users [ table 14 ] . insulin aspartoral glucose - lowering drug safety data mean hba1c and mean pppg improved from baseline to study end in those who started on or were switched insulin aspart  oglds [ table 16 ] . insulin aspartoral glucose - lowering drug efficacy data our study reports improved glycaemic control and quality of life following 24 weeks of treatment with any of the insulin analogues ( biphasic insulin aspart ; basal + insulin aspart ; insulin detemir ; insulin aspart ) with or without ogld . though the findings are limited by number of patients , still the trend indicates that insulin analogues can be considered effective and possess a safe profile for treating type 2 diabetes in rabat - sale - zemmour - zaer region , morocco .
background : the a1chieve , a multicentric ( 28 countries ) , 24-week , non - interventional study evaluated the safety and effectiveness of insulin detemir , biphasic insulin aspart and insulin aspart in people with t2 dm ( n = 66 726 ) in routine clinical care across four continents.materials and methods : data was collected at baseline , at 12 weeks and at 24 weeks . this short communication presents the results for patients enrolled from rabat - sale - zemmour - zaer region , morocco.results:a total of 424 patients were enrolled in the study . 
 four different insulin analogue regimens were used in the study . 
 study patients had started on or were switched to biphasic insulin aspart ( n = 177 ) , insulin detemir ( n = 150 ) , insulin aspart ( n = 11 ) , basal insulin plus insulin aspart ( n = 45 ) and other insulin combinations ( n = 41 ) . at baseline 
 glycaemic control was poor for both insulin nave ( mean hba1c : 10.1% ) and insulin user ( mean hba1c : 9.4% ) groups . 
 after 24 weeks of treatment , all the study groups showed improvement in hba1c ( insulin nave : 2.5% , insulin users : 1.8% ) . 
 major hypoglycaemia was observed in the insulin user group after 24 weeks ( 0.1 events / patient - year ) . 
 sadrs were reported in 0.5% of insulin users.conclusion:starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia .